Myasthenia Gravis: all 327 studies
Page 1 of 4. Open to participants first (144), then studies with results posted, then the rest; newest registration first within each.
- Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia GravisNot yet recruitingNCT07853378
- An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia GravisNot yet recruitingNCT07818291Phase 1
- Feasibility of Remote Monitoring of Patients With Myasthenia GravisRecruitingNCT07787247
- AXIS MG Patient RegistryRecruitingNCT07761026
- PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia GravisRecruitingNCT07717281
- Universal STAR-T Cell Injection in Generalized Myasthenia GravisNot yet recruitingNCT07714798Phase 1
- Sexual and Urinary Dysfunctions in Generalized MyastheniaNot yet recruitingNCT07677852
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyNot yet recruitingNCT07676266Phase 1
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingNCT07673744Phase 2
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisRecruitingNCT07673627Phase 2
- Cohort Study on Neuroimmune Diseases in the Reproductive AgeRecruitingNCT07653984
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)RecruitingNCT07647510Phase 3
- A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisRecruitingNCT07622342Phase 2
- Study of Aritinercept in Patients With Generalized Myasthenia GravisRecruitingNCT07596901Phase 1/2
- Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)RecruitingNCT07596784Phase 3
- A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in ItalyRecruitingNCT07595653
- A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune DiseasesNot yet recruitingNCT07593911Not applicable
- Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia GravisNot yet recruitingNCT07571525
- Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)RecruitingNCT07570589
- Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)Not yet recruitingNCT07556120Phase 1
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.RecruitingNCT07526493Phase 1
- The Effectiveness of an ETP Programme in Myasthenia Gravis: a Proof-of-concept Study.Not yet recruitingNCT07512375
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisRecruitingNCT07501702Phase 2
- Talquetamab in Patients With Refractory Generalized Myasthenia GravisNot yet recruitingNCT07499323Not applicable
- Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseRecruitingNCT07478172Not applicable
- Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesRecruitingNCT07470151Not applicable
- A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07465289Phase 3
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingNCT07463521Phase 3
- Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)RecruitingNCT07413835Not applicable
- Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG CrisisRecruitingNCT07411963
- Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune DiseasesNot yet recruitingNCT07392528Early Phase 1
- Ripertamab for the Treatment of Myasthenia GravisNot yet recruitingNCT07372807Phase 1/2
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune DiseasesRecruitingNCT07337785Early Phase 1
- Proteomic Changes in Patients With Myasthenia Gravis and RavulizumabNot yet recruitingNCT07337395
- Tongji NADs CohortNot yet recruitingNCT07333196
- Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360Not yet recruitingNCT07323316Not applicable
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentRecruitingNCT07304154Phase 1
- A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNCT07298928Not applicable
- ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia GravisRecruitingNCT07294170
- ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodRecruitingNCT07284420Phase 2
- A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisRecruitingNCT07250750Phase 1/2
- A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingNCT07249632Phase 3
- Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in RussiaRecruitingNCT07247279
- Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisRecruitingNCT07246564Phase 4
- Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia GravisNot yet recruitingNCT07243366Early Phase 1
- Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MGNot yet recruitingNCT07226830
- Multi-Modal Monitoring of Disease Symptoms in Myasthenia GravisNot yet recruitingNCT07224386
- A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabRecruitingNCT07221838Phase 4
- Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia GravisRecruitingNCT07217587Phase 3
- PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness RegistryEnrolling by invitationNCT07217509
- Zilucoplan for Severe gMG ExacerbationsRecruitingNCT07215949Phase 3
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Phase 1
- Construction of A Multimodal Digital Assessment Model for Myasthenia GravisRecruitingNCT07146425
- Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic PathologyRecruitingNCT07136844Not applicable
- Integrating Art Therapy and Adapted Physical Activity: Toward Improved Quality of Life in Patients With Myasthenia GravisNot yet recruitingNCT07125105Not applicable
- Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune DiseasesRecruitingNCT07085676Phase 1
- Efgartigimod for Consolidation Therapy in gMGNot yet recruitingNCT07079020
- Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC EfgartigimodRecruitingNCT07072988Phase 4
- GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)RecruitingNCT07058298Early Phase 1
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisRecruitingNCT07039916Phase 3
- Detecting Fatigue From Voice in Generalised Myasthenia GravisNot yet recruitingNCT07033559
- Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune DiseasesRecruitingNCT07022197Phase 1/2
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)RecruitingNCT06987539Phase 2
- UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune DiseasesNot yet recruitingNCT06978738Phase 1
- Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia GravisRecruitingNCT06967480
- Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)RecruitingNCT06940323
- Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune DiseasesRecruitingNCT06939166Early Phase 1
- UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia GravisNot yet recruitingNCT06933563Early Phase 1
- Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia GravisRecruitingNCT06909253
- The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia GravisRecruitingNCT06881173Not applicable
- Application of Artificial Intelligence in Precision Medicine and HealthcareRecruitingNCT06879210Not applicable
- Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My" AstheniaEnrolling by invitationNCT06877403
- Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"RecruitingNCT06866652
- Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated AssessmentRecruitingNCT06866483
- Blinatumomab for Treatment of Refractory Myasthenia GravisNot yet recruitingNCT06836973Phase 2/3
- Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia GravisNot yet recruitingNCT06827587Not applicable
- Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 MonthsRecruitingNCT06815133
- Dixon MRI Imaging Histology for Predicting Postoperative Infection in Posterior Lumbar Fusion for Myasthenia GravisNot yet recruitingNCT06805643
- Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University HospitalsNot yet recruitingNCT06774937
- Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsRecruitingNCT06765161Phase 3
- An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingNCT06759948Phase 1
- TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy ControlsRecruitingNCT06754020Not applicable
- Capturing Key MG-symptoms Using Smartphone Recordings.RecruitingNCT06743490
- Telitacicept and Low-dose Steroids in Refractory Myasthenia GravisNot yet recruitingNCT06723548Phase 4
- A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia GravisRecruitingNCT06688435Phase 1
- Markers of Favorable Response to FcRn Inhibitors(INFORM)RecruitingNCT06685055
- Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)Not yet recruitingNCT06684184Phase 2/3
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersRecruitingNCT06680037Phase 1
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingNCT06626919Phase 1
- Myasthenia Gravis Foundation of America Global MG Patient RegistryRecruitingNCT06617741
- PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisRecruitingNCT06607627Phase 3
- Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular DisordersEnrolling by invitationNCT06605612
- Seronegative Myasthenia Gravis - Efgartigimod IVRecruitingNCT06587867Phase 3
- FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesRecruitingNCT06539169
- Biomarkers in Autoimmune Disease of Nervous SystemRecruitingNCT06502015
- Light vs. Moderate Intensity Exercise in Individuals With Myasthenia GravisRecruitingNCT06491238Not applicable
- Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.Not yet recruitingNCT06485232Early Phase 1
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Phase 3
- Markers of Favorable Response to Complement Inhibitors TherapyRecruitingNCT06455709
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Phase 2/3